Genmab — Maj 2020

[AaBforever]

Sidder lige og overvejer om de skal slippes løs i dag.

[Legolas23]

@Mcjean

[Darvin]

Og her - gevinsthjemtagning i morgen ?

[AaBforever]

Det er det store spørgsmål?? ASCO??

[Darvin]

Eller naturligt efter stor stigning ?

[nohope]

Når nu det er et krav at regeringen griber i prisdannelsen på sko og tøj, så synes jeg de burde regulere prisen på GEN også.

[E_L]

[E_L]

interesting daily candle for the TA crowd, green, engulfing, closed yesterdays gap, closed practically equal from yesterday after a 4.5% move. very rare

[Legolas23]

Its is

[Legolas23]

Its is a very strong and tough canndle.

[E_L]

you often see a bullish engulfing candle at a, or signalling a bottom, following a red candle

[E_L]

we'll see tomorrow what this one means

[Helge_LarsenPI-redaktør]

Vi har før prøvet tilsvarende kursudvikling på dage med storudsalg af warrants. Hvilke det er husker jeg ikke på stående fod.

[transalp]

Pokkers.. i morges tippede jeg grøn luk..

[GMAB]

Conclusions:
SC epcoritamab continues to demonstrate a favorable safety profile across all doses with no ≥Gr 3 CRS and no DLTs. Dose escalation data show improved efficacy as doses reach above the modeled predicted exposure threshold, inducing CRs in heavily pretreated DLBCL pts. All pts achieving CRs remain in remission. Clinical trial information: NCT03625037.

Anti-tumor activity in R/R B-NHL.
DLBCL/HGBCL ≥6 mg (n=12) FL ≥0.76 mg (n=7)
Evaluable pts 9 6
ORR, n(%) CR
PR 5 (56%) 4 (44%)
1 (11%)

[E_L]

https://meetinglibrary.asco.org/record/186016/abstract

[Sukkeralf]

Okay looks good - and data will be further updated at the ASCO meeting

[E_L]

no ≥Gr 3 CRS and no DLTs ; i guess that is the most important for now?

[E_L]

"Treatment is ongoing in 13 pts " from 41 does not seem much? or should i not read anyting into that?

[E_L]

then again, very ill patients with 3 to 5 prior lines of treatment.